Group 1: Company Certifications and Capabilities - The company has obtained multiple certifications including FDA510(k), EU MDR, ISO9001, ISO13485, and others, enabling it to meet global market entry requirements [5] - The company holds a medical device production license and registration certificate, ensuring compliance with industry standards [5] Group 2: Cost Control Measures - Current cost control measures include self-developed chip applications, production process optimization, and efficiency improvements [6] - Future plans to reduce costs involve assimilating technology from the acquisition of Intricon, promoting modular product design, and implementing budget control [6] Group 3: Competitive Advantages and Strategies - The company has established a vertical layout in the hearing aid industry, focusing on chip design, algorithm research, and channel development [7] - The technical team has mastered core technologies such as DSP digital hearing aid chip design and sound processing algorithms, providing a competitive edge [7] Group 4: Financial Performance and Growth - In 2024, the company experienced a 49% decline in profit due to increased sales expenses from expanding its own brand channels [8] - The first quarter of the current year showed significant growth in self-owned brand sales revenue, indicating early success from the previous year's channel expansion [8] Group 5: Research and Development Plans - The company plans to maintain reasonable R&D investment intensity based on project progress [9] - There are plans to enhance operational efficiency in offline stores and adapt to market changes for store expansion [9] Group 6: Customer Base and Order Acquisition - The customer base has expanded to include new overseas supermarket channels for self-owned brands, while new order acquisition remains stable [10] - The company continues to focus on its existing B-end customer base while integrating new clients [10] Group 7: Core Business Advantages - The establishment of the subsidiary Chip Sea Ling in 2020 has enabled the development of self-researched DSP digital hearing aid chips, which significantly reduce manufacturing costs [11] - The company has achieved mass production of its first-generation self-developed chip, with approximately 780,000 units integrated into products [12]
锦好医疗(872925) - 投资者关系活动记录表